Novartis rejects suspected data manipulation in US
Swiss pharmaceutical company Novartis has dismissed criticism that it allegedly withheld information about animal testing data inaccuracies to United States authorities for a human gene therapy.
This content was published on
1 minute
swissinfo.ch/ug
NovartisExternal link said its subsidiary in California began investigating the alleged data manipulation for its gene therapy Zolgensma as soon as it learned about it. Once the company had interim conclusions, it shared the informationExternal link with the US Food and Drug Administration (FDA).
The agency said Novartis did not disclose the information about suspected data manipulation until after the $2.1 million (CHF2.1) therapy treatment for children under the age of two won approval by the US regulator in May.
In a statement, the pharma company explained that the data in question were a small portion of its overall submission and limited to an older process no longer in use.
“The assays in question were used for initial product testing and are nor currently used for commercial product release,” Novartis said.
According to the company, Zolgensma, the most expensive treatment ever, is safe, of high quality and effective in treating patients with spinal muscular atrophy.
The FDA has indicated that the drug will remain on the market. The company’s actions are being assessed and could lead to criminal or civil penalties if appropriate.
More
More
How can a drug cost $2.1 million?
This content was published on
US authorities have approved a $2.1 million gene therapy, making it the most expensive drug ever. Can such a price tag be justified?
Switzerland abstains from vote on Palestinian bid for full UN membership
This content was published on
On Friday, Switzerland abstained from the vote at the General Assembly on granting the Palestinians new rights at the United Nations (UN).
Protein in abdominal fat could help shape obesity treatment
This content was published on
The study analysed fat cells from different locations in the body, and found that those in the abdomen have unique properties.
North African asylum claims fall after rapid Swiss processing
This content was published on
The accelerated procedure, now out of its test phase, has resulted in a significant drop in applications from North African countries.
This content was published on
The artist's song "The Code" focuses on their journey as a nonbinary individual. It is one of the favourites to win this year's contest.
Swiss climate activists block vehicles near Gotthard tunnel
This content was published on
Around ten climate activists briefly blocked the A2 motorway near the northern entrance of the Gotthard tunnel on Thursday.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Pharma company Sandoz named in US price-fixing lawsuit
This content was published on
The Germany-based subsidiary of Novartis is targeted in a 44-state class action suit for breaching rules on fair competition.
This content was published on
Swiss pharmaceutical Novartis must face a US government lawsuit accusing it of paying millions of dollars in kickbacks to doctors.
This content was published on
Pressure groups Public Eye and Médecins du Monde have filed their objection to the European patent office in Munich. They claim that Kymriah was not invented by Novartis because the research behind the drug was carried out by public institutions. The medicament, which is used to treat leukaemia and lymph gland cancer on patients who have…
Novartis faces questions about proxy voting independence
This content was published on
Proxy votes submitted by shareholders ended up at Novartis headquarters instead of the elected representative ahead of the annual general meeting.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.